跳至主要内容
临床试验/NCT01147731
NCT01147731已完成1 期

An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects

GlaxoSmithKline2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2010年6月4日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
16
试验地点
2
主要终点
The pharmacokinetic parameters (AUC and Cmax) of R and S-warfarin isomers with and without albiglutide

研究概览

简要总结

This open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of warfarin.

详细描述

This Phase I open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of warfarin.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • male healthy volunteers in good health
  • no clinically significant diseases or clinically significant abnormal laboratory values
  • body mass index (BMI) is >/=18 kg and ≤30 kg/m2
  • nonsmoker

排除标准

  • positive test results for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
  • any clinically relevant abnormality
  • history of any anaphylactic reaction to any drug
  • history of significant cardiovascular or pulmonary dysfunction
  • history of excessive bleeding
  • current or chronic history of liver disease
  • history of alcohol or substance abuse
  • history of thyroid disease or dysfunction
  • history of gastrointestinal surgery or disease
  • history of pancreatitis
  • previously received any GLP-1 mimetic compound (e.g., exenatide)

结局指标

主要结局

The pharmacokinetic parameters (AUC and Cmax) of R and S-warfarin isomers with and without albiglutide

时间窗: 52 days

次要结局

  • The effect of albiglutide on the pharmacodynamics of warfarin as determined by the International Normalisation Ratio (INR).(52 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验